Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2O Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
/PRNewswire/ Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome.
Epigenic Therapeutics and Ronovo Surgical have raised new funding to advance their product R&D, while Trustar Capital is selling Moritex to Cognex Corp.